Pacira | PCRX - Umsatzkosten





Umsatzkosten Veränderung Datum
Astellas Pharma JPY 129.43B 19.7B 2026-03
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Cara Therapeutics USD 0 0 2025-03
Coherus Biosciences USD 4.04M 324K 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
J&J USD 8B 67M 2026-06
Ligand Pharmaceuticals USD 11.37M 8.38M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Novo Nordisk DKK 13.6B 1.55B 2026-03
Omeros USD 33.16M 18.52M 2024-06
Pacira USD 50.74M 3.89M 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Supernus Pharmaceuticals USD 49.04M 1.5M 2026-03
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Xeris Pharmaceuticals USD 10.57M 3.08M 2026-03
Zoetis USD 672M 71M 2026-03